Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model

The poor prognosis in non-small-cell lung cancer has driven the development of novel targeted therapies. Vascular endothelial growth factor is the most potent force in mediating tumor angiogenesis, and many angiogenesis inhibitors have been developed for oncology treatment. We performed a study to c...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Yinghua, Wei, Lingxiao, Jiang, Qiuying, Song, Xiaowei, Teng, Chong, Fan, Chengjuan, Lv, Yanju, Liu, Ying, Shen, Weixi, Li, Li, Huang, Dayong, Xin, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203857/
https://www.ncbi.nlm.nih.gov/pubmed/30367145
http://dx.doi.org/10.1038/s41598-018-34030-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203857/
https://www.ncbi.nlm.nih.gov/pubmed/30367145
http://dx.doi.org/10.1038/s41598-018-34030-5

Ejemplares similares